Corcept Therapeutics Incorporated (CORT)
Working capital turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 482,375 | 450,026 | 428,153 | 413,824 | 401,858 | 397,624 | 392,027 | 380,229 | 365,978 | 352,891 | 343,087 | 340,064 | 353,874 | 356,034 | 351,212 | 334,904 | 306,486 | 285,422 | 268,362 | 258,417 |
Total current assets | US$ in thousands | 458,636 | 431,527 | 432,588 | 533,893 | 499,253 | 452,402 | 419,045 | 388,220 | 266,463 | 401,900 | 411,270 | 409,624 | 478,501 | 463,493 | 438,333 | 344,776 | 307,358 | 267,310 | 232,655 | 216,864 |
Total current liabilities | US$ in thousands | 104,505 | 121,873 | 93,059 | 78,865 | 72,491 | 53,068 | 49,057 | 57,244 | 47,541 | 44,757 | 45,402 | 40,601 | 47,494 | 43,048 | 42,243 | 34,075 | 38,841 | 32,396 | 30,381 | 34,218 |
Working capital turnover | 1.36 | 1.45 | 1.26 | 0.91 | 0.94 | 1.00 | 1.06 | 1.15 | 1.67 | 0.99 | 0.94 | 0.92 | 0.82 | 0.85 | 0.89 | 1.08 | 1.14 | 1.22 | 1.33 | 1.41 |
December 31, 2023 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $482,375K ÷ ($458,636K – $104,505K)
= 1.36
The working capital turnover of Corcept Therapeutics Inc has shown some variability over the past eight quarters. The working capital turnover ratio measures how efficiently a company is utilizing its working capital to generate sales revenue.
From Q1 2022 to Q2 2023, the working capital turnover ratio fluctuated between 0.91 and 1.45. Notably, the ratio peaked in Q3 2023 at 1.45 and was at its lowest in Q1 2023 at 0.91. A higher working capital turnover ratio signifies that the company is able to generate more revenue with its current level of working capital.
Overall, despite some fluctuations, the working capital turnover ratio of Corcept Therapeutics Inc has generally been above 1, indicating that the company has been effectively utilizing its working capital to support its sales activities. However, it would be beneficial to further investigate the reasons behind the variations in the ratio to ensure sustained efficiency in working capital management.
Peer comparison
Dec 31, 2023